Non-Alcoholic Fatty Liver Disease: Is Bariatric Surgery the Answer?

Clinics in Liver Disease

Volumn 13, Issue 4, 2009, Pages 689-710

  Pillai, Anjana A ^a   Rinella, Mary E ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Bariatric surgery; Gastric banding; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis; Roux en Y gastric bypass

Indexed keywords

GHRELIN; GLUCAGON LIKE PEPTIDE 1; PEPTIDE YY; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

ADJUSTABLE GASTRIC BANDING; BARIATRIC SURGERY; BILIOPANCREATIC BYPASS; CALORIC RESTRICTION; CLINICAL TRIAL; COMORBIDITY; DIABETES MELLITUS; DIET; DISEASE COURSE; EXERCISE; FATTY LIVER; GLUCOSE HOMEOSTASIS; HEPATITIS; HUMAN; JEJUNOILEAL BYPASS; LIFESTYLE MODIFICATION; LIVER FAILURE; LIVER TRANSPLANTATION; METABOLIC SYNDROME X; MORBID OBESITY; MORBIDITY; MORTALITY; NONALCOHOLIC FATTY LIVER; OBESITY; PATIENT SAFETY; PATIENT SELECTION; RECURRENT DISEASE; REVIEW; RISK FACTOR; ROUX Y ANASTOMOSIS; SLEEVE GASTRECTOMY; SURGICAL TECHNIQUE; VERTICAL BANDED GASTROPLASTY; WEIGHT REDUCTION;

BARIATRIC SURGERY; FATTY LIVER; HUMANS; OBESITY; TREATMENT OUTCOME;

EID: 70349771924     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2009.07.012     Document Type: Review

References (112)

1. Browning J.D., Szczepaniak L.S., Dobbins R., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40 (2004) 1387-1395
2. Lazo M., and Clark J.M. The epidemiology of no-nalcoholic fatty liver disease: a global perspective. Semin Liver Dis 28 (2008) 339-350
3. Wanless I.R., and Lentz J.S. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 12 (1990) 1106-1110
4. World Health Organization, obesity and overweight, 2009. Available at: http://www.who.int/dietphysicalactivity/media/en/gsfs_obesity.pdf. Accessed July, 2009.
5. CDC/NCHS, National Health and Nutrition Examination Survey, 2005-2006. Available at: http://www.cdc.gov/nchs/products/pubs/pubd/hestats/overweight/overweight_adult.pdf. Accessed July, 2009.
6. Burke A., and Lucey M.R. Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and orthotopic liver transplantation. Am J Transplant 4 (2004) 686-693
7. Adams K.F., Schatzkin A., Harris T.B., et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med 355 (2006) 763-778
8. Vuppalanchi R., and Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology 49 (2009) 306-317
9. Chitturi S., Abeygunasekera S., Farrell G.C., et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 35 (2002) 373-379
10. Marchesini G., Bugianesi E., Forlani G., et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37 (2003) 917-923
11. Pagano G., Pacini G., Musso G., et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 35 (2002) 367-372
12. Ratziu V., Giral P., Charlotte F., et al. Liver fibrosis in overweight patients. Gastroenterology 118 (2000) 1117-1123
13. Angulo P., Keach J.C., Batts K.P., et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 30 (1999) 1356-1362
14. Powell E.E., Cooksley W.G., Hanson R., et al. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 11 (1990) 74-80
15. Hui J.M., Kench J.G., Chitturi S., et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 38 (2003) 420-427
16. Harrison S.A., and Di Bisceglie A.M. Advances in the understanding and treatment of nonalcoholic fatty liver disease. Drugs 63 (2003) 2379-2394
17. Fassio E., Alvarez E., Dominguez N., et al. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 40 (2004) 820-826
18. Adams L.A., and Angulo P. Recent concepts in non-alcoholic fatty liver disease. Diabet Med 22 (2005) 1129-1133
19. Dandona P., Aljada A., and Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 25 (2004) 4-7
20. Kaplan L.M. Leptin, obesity, and liver disease. Gastroenterology 115 (1998) 997-1001
21. Klein S., Fontana L., Young V.L., et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med 350 (2004) 2549-2557
22. Samuel V.T., Liu Z.X., Qu X., et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 279 (2004) 32345-32353
23. Calle E.E., Rodriguez C., Walker-Thurmond K., Thun M.J., et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348 (2003) 1625-1638
24. Rafiq N., Bai C., Fang Y., et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 7 (2009) 234-238
25. Bugianesi E. Nonalcoholic fatty liver disease (NAFLD) and cardiac lipotoxicity: another piece of the puzzle. Hepatology 47 (2008) 2-4
26. Adams L.A., Lymp J.F., St Sauver J., et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129 (2005) 113-121
27. Loria P., Lonardo A., Bellentani S., et al. Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: an open question. Nutr Metab Cardiovasc Dis 17 (2007) 684-698
28. Targher G., Bertolini L., Padovani R., et al. Increased prevalence of cardiovascular disease in type 2 diabetic patients with non-alcoholic fatty liver disease. Diabet Med 23 (2006) 403-409
29. Kadayifci A., Tan V., Ursell P.C., et al. Clinical and pathologic risk factors for atherosclerosis in cirrhosis: a comparison between NASH-related cirrhosis and cirrhosis due to other aetiologies. J Hepatol 49 (2008) 595-599
30. Ong J.P., Pitts A., and Younossi Z.M. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol 49 (2008) 608-612
31. Brea A., Mosquera D., Martin E., et al. Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study. Arterioscler Thromb Vasc Biol 25 (2005) 1045-1050
32. Targher G. Associations between liver histology and early carotid atherosclerosis in subjects with nonalcoholic fatty liver disease. Hepatology 42 (2005) 974-975 [discussion: 975]
33. Targher G., Bertolini L., Padovani R., et al. Associations between liver histology and carotid intima-media thickness in patients with nonalcoholic fatty liver disease. Arterioscler Thromb Vasc Biol 25 (2005) 2687-2688
34. Villanova N., Moscatiello S., Ramilli S., et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 42 (2005) 473-480
35. Huang M.A., Greenson J.K., Chao C., et al. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol 100 (2005) 1072-1081
36. Palmer M., and Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 99 (1990) 1408-1413
37. Ueno T., Sugawara H., Sujaku K., et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 27 (1997) 103-107
38. Clark J.M. Weight loss as a treatment for nonalcoholic fatty liver disease. J Clin Gastroenterol 40 Suppl 1 (2006) S39-S43
39. Harrison S.A., Fincke C., Helinski D., et al. A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. Aliment Pharmacol Ther 20 (2004) 623-628
40. Hatzitolios A., Savopoulos C., Lazaraki G., et al. Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia. Indian J Gastroenterol 23 (2004) 131-134
41. Sabuncu T., Nazligul Y., Karaoglanoglu M., et al. The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis. Rom J Gastroenterol 12 (2003) 189-192
42. Harrison S.A., Fecht W., Brunt E.M., et al. Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. Hepatology 49 (2009) 80-86
43. Pi-Sunyer F.X., Aronne L.J., Heshmati H.M., et al., RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295 (2006) 761-775
44. Van Gaal L.F., Rissanen A.M., Scheen A.J., et al., RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365 (2005) 1389-1397
45. Kashi M.R., Torres D.M., and Harrison S.A. Current and emerging therapies in nonalcoholic fatty liver disease. Semin Liver Dis 28 (2008) 396-406
46. NIH conference. Gastrointestinal surgery for severe obesity. Consensus Development Conference Panel. Ann Intern Med (1991)
47. Elder K.A., and Wolfe B.M. Bariatric surgery: a review of procedures and outcomes. Gastroenterology 132 (2007) 2253-2271
48. Tsai A.G., Asch D.A., and Wadden T.A. Insurance coverage for obesity treatment. J Am Diet Assoc 106 (2006) 1651-1655
49. Zhao Y., and Encinosa W. CT bariatric surgery utilization and outcomes in 1998 and 2004. Statistical brief #23 (January 2007), Agency for Healthcare Research and Quality, Rockville (MD)
50. Verna E.C., and Berk P.D. Role of fatty acids in the pathogenesis of obesity and fatty liver: impact of bariatric surgery. Semin Liver Dis 28 (2008) 407-426
51. Andersen T., Gluud C., Franzmann M.B., et al. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol 12 (1991) 224-229
52. Scopinaro N., Gianetta E., Civalleri D., et al. Bilio-pancreatic bypass for obesity: II. Initial experience in man. Br J Surg 66 (1979) 618-620
53. Marceau P., Biron S., Bourque R.A., et al. Biliopancreatic diversion with a new type of gastrectomy. Obes Surg 3 (1993) 29-35
54. Fontaine K.R., Redden D.T., Wang C., et al. Years of life lost due to obesity. JAMA 289 (2003) 187-193
55. Buchwald H., Avidor Y., Braunwald E., et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 292 (2004) 1724-1737
56. Adams T.D., Gress R.E., Smith S.C., et al. Long-term mortality after gastric bypass surgery. N Engl J Med 357 (2007) 753-761
57. Sjostrom L., Lindroos A.K., Peltonen M., et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 351 (2004) 2683-2693
58. Sjostrom L., Narbro K., Sjostrom C.D., et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 357 (2007) 741-752
59. Mottin C.C., Moretto M., Padoin A.V., et al. Histological behavior of hepatic steatosis in morbidly obese patients after weight loss induced by bariatric surgery. Obes Surg 15 (2005) 788-793
60. Clark J.M., Alkhuraishi A.R., Solga S.F., et al. Roux-en-Y gastric bypass improves liver histology in patients with non-alcoholic fatty liver disease. Obes Res 13 (2005) 1180-1186
61. Mattar S.G., Velcu L.M., Rabinovitz M., et al. Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Ann Surg 242 (2005) 610-617 [discussion: 618-20]
62. Mathurin P., Gonzalez F., Kerdraon O., et al. The evolution of severe steatosis after bariatric surgery is related to insulin resistance. Gastroenterology 130 (2006) 1617-1624
63. Csendes A., Smok G., and Burgos A.M. Histological findings in the liver before and after gastric bypass. Obes Surg 16 (2006) 607-611
64. de Almeida S.R., Rocha P.R., Sanches M.D., et al. Roux-en-Y gastric bypass improves the nonalcoholic steatohepatitis (NASH) of morbid obesity. Obes Surg 16 (2006) 270-278
65. Dixon J.B., Bhathal P.S., and O'Brien P.E. Weight loss and non-alcoholic fatty liver disease: falls in gamma-glutamyl transferase concentrations are associated with histologic improvement. Obes Surg 16 (2006) 1278-1286
66. Barker K.B., Palekar N.A., Bowers S.P., et al. Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery. Am J Gastroenterol 101 (2006) 368-373
67. Liu X., Lazenby A.J., Clements R.H., et al. Resolution of nonalcoholic steatohepatitis after gastric bypass surgery. Obes Surg 17 (2007) 486-492
68. Furuya Jr. C.K., de Oliveira C.P., de Mello E.S., et al. Effects of bariatric surgery on nonalcoholic fatty liver disease: preliminary findings after 2 years. J Gastroenterol Hepatol 22 (2007) 510-514
69. Luyckx F.H., Desaive C., Thiry A., et al. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord 22 (1998) 222-226
70. Ranlov I., and Hardt F. Regression of liver steatosis following gastroplasty or gastric bypass for morbid obesity. Digestion 47 (1990) 208-214
71. Grimm I.S., Schindler W., and Haluszka O. Steatohepatitis and fatal hepatic failure after biliopancreatic diversion. Am J Gastroenterol 87 (1992) 775-779
72. Cotler S.J., Vitello J.M., Guzman G., et al. Hepatic decompensation after gastric bypass surgery for severe obesity. Dig Dis Sci 49 (2004) 1563-1568
73. Dixon J.B., Bhathal P.S., Hughes N.R., et al. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology 39 (2004) 1647-1654
74. Kral J.G., Thung S.N., Biron S., et al. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery 135 (2004) 48-58
75. Silverman E.M., Sapala J.A., and Appelman H.D. Regression of hepatic steatosis in morbidly obese persons after gastric bypass. Am J Clin Pathol 104 (1995) 23-31
76. Eriksson F. Biliointestinal bypass. Int J Obes 5 (1981) 437-447
77. Klein S., Mittendorfer B., Eagon J.C., et al. Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease. Gastroenterology 130 (2006) 1564-1572
78. Laferrere B., Heshka S., Wang K., et al. Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care 30 (2007) 1709-1716
79. le Roux C.W., Welbourn R., Werling M., et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg 246 (2007) 780-785
80. Bose M., Olivan B., Teixeira J., et al. Do incretins play a role in the remission of type 2 diabetes after gastric bypass surgery: what are the evidence?. Obes Surg 19 (2009) 217-229
81. Korner J., Bessler M., Cirilo L.J., et al. Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin. J Clin Endocrinol Metab 90 (2005) 359-365
82. Korner J., Bessler M., Inabnet W., et al. Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Surg Obes Relat Dis 3 (2007) 597-601
83. Korner J., Inabnet W., Conwell I.M., et al. Differential effects of gastric bypass and banding on circulating gut hormone and leptin levels. Obesity (Silver Spring) 14 (2006) 1553-1561
84. Ding X., Saxena N.K., Lin S., et al. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 43 (2006) 173-181
85. Lee Y.S., Shin S., Shigihara T., et al. Glucagon-like peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis. Diabetes 56 (2007) 1671-1679
86. Tushuizen M.E., Bunck M.C., Pouwels P.J., et al. Incretin mimetics as a novel therapeutic option for hepatic steatosis. Liver Int 26 (2006) 1015-1017
87. Chitturi S., Farrell G., Frost L., et al. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: A manifestation of lipotoxicity?. Hepatology 36 (2002) 403-409
88. Chalasani N., Crabb D.W., Cummings O.W., et al. Does leptin play a role in the pathogenesis of human nonalcoholic steatohepatitis?. Am J Gastroenterol 98 (2003) 2771-2776
89. Angulo P., Alba L.M., Petrovic L.M., et al. Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J Hepatol 41 (2004) 943-949
90. Javor E.D., Ghany M.G., Cochran E.K., et al. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. Hepatology 41 (2005) 753-760
91. Cummings D.E., Weigle D.S., Frayo R.S., et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 346 (2002) 1623-1630
92. Faraj M., Havel P.J., Phelis S., et al. Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 88 (2003) 1594-1602
93. Foschi D., Corsi F., Colombo F., et al. Different effects of vertical banded gastroplasty and Roux-en-Y gastric bypass on meal inhibition of ghrelin secretion in morbidly obese patients. J Invest Surg 21 (2008) 77-81
94. Goldfine A.B., Mun E.C., Devine E., et al. Patients with neuroglycopenia after gastric bypass surgery have exaggerated incretin and insulin secretory responses to a mixed meal. J Clin Endocrinol Metab 92 (2007) 4678-4685
95. Brolin R.E., Bradley L.J., and Taliwal R.V. Unsuspected cirrhosis discovered during elective obesity operations. Arch Surg 133 (1998) 84-88
96. Dallal R.M., Mattar S.G., Lord J.L., et al. Results of laparoscopic gastric bypass in patients with cirrhosis. Obes Surg 14 (2004) 47-53
97. Ong J., Younossi Z.M., Reddy V., et al. Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. Liver Transpl 7 (2001) 797-801
98. Contos M.J., Cales W., Sterling R.K., et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl 7 (2001) 363-373
99. Garcia R.F., Morales E., Garcia C.E., et al. Recurrent and de novo nonalcoholic steatohepatitis following orthotopic liver transplantation. Arq Gastroenterol 38 (2001) 247-253
100. Poordad F., Gish R., Wakil A., et al. De novo non-alcoholic fatty liver disease following orthotopic liver transplantation. Am J Transplant 3 (2003) 1413-1417
101. Butte J.M., Devaud N., Jarufe N.P., et al. Sleeve gastrectomy as treatment for severe obesity after orthotopic liver transplantation. Obes Surg 17 (2007) 1517-1519
102. Duchini A., and Brunson M.E. Roux-en-Y gastric bypass for recurrent nonalcoholic steatohepatitis in liver transplant recipients with morbid obesity. Transplantation 72 (2001) 156-159
103. Tichansky D.S., and Madan A.K. Laparoscopic Roux-en-Y gastric bypass is safe and feasible after orthotopic liver transplantation. Obes Surg 15 (2005) 1481-1486
104. Campsen J., Zimmerman M., Shoen J., et al. Adjustable gastric banding in a morbidly obese patient during liver transplantation. Obes Surg 18 (2008) 1625-1627
105. Lewis M.C., Phillips M.L., Slavotinek J.P., et al. Change in liver size and fat content after treatment with Optifast very low calorie diet. Obes Surg 16 (2006) 697-701
106. Benjaminov O., Beglaibter N., Gindy L., et al. The effect of a low-carbohydrate diet on the nonalcoholic fatty liver in morbidly obese patients before bariatric surgery. Surg Endosc 21 (2007) 1423-1427
107. Alfalah H., Philippe B., Ghazal F., et al. Intragastric balloon for preoperative weight reduction in candidates for laparoscopic gastric bypass with massive obesity. Obes Surg 16 (2006) 147-150
108. Frutos M.D., Morales M.D., Lujan J., et al. Intragastric balloon reduces liver volume in super-obese patients, facilitating subsequent laparoscopic gastric bypass. Obes Surg 17 (2007) 150-154
109. Lopasso F.P., Sakai P., Gazi B.M., et al. A pilot study to evaluate the safety, tolerance, and efficacy of a novel stationary antral balloon (SAB) for obesity. J Clin Gastroenterol 42 (2008) 48-53
110. Ricci G., Bersani G., Rossi A., et al. Bariatric therapy with intragastric balloon improves liver dysfunction and insulin resistance in obese patients. Obes Surg 18 (2008) 1438-1442
111. Trande P., Mussetto A., Mirante V.G., et al. Efficacy, tolerance and safety of new intragastric air-filled balloon (heliosphere BAG) for obesity: the experience of 17 cases. Obes Surg (2008). DOI: 10.1007/s11695-008-9786-2
112. Dumonceau J.M. Evidence-based review of the bioenterics intragastric balloon for weight loss. Obes Surg 18 (2008) 1611-1617